Positron Emission Tomography in the diagnosis of an unknown primary tumour

Authors

  • Sandra Simões Interna de Medicina Interna, Serviço de Medicina III, Hospitais da Universidade de Coimbra
  • Teresa Vaio Assistente Eventual de Medicina Interna, Serviço de Medicina III, Hospitais da Universidade de Coimbra
  • Arsénio Santos Assistente Graduado de Medicina Interna, Serviço Medicina III, Hospitais da Universidade de Coimbra
  • Rui Santos Chefe de Serviço de Medicina Interna, Serviço de Medicina III e Professor Auxiliar da Faculdade de Medicina da Universidade de Coimbra
  • Paula Lapa Assistente Hospitalar de Medicina Nuclear, Serviço de Medicina Nuclear, Hospitais da Universidade de Coimbra
  • Pedroso de Lima Chefe de Serviço de Medicina Nuclear – HUC e Professor Auxiliar Convidado da Faculdade de Medicina da Universidade de Coimbra
  • Ana Antunes Directora do Serviço de Medicina Nuclear, Hospitais da Universidade de Coimbra
  • Armando Porto Director do Serviço de Medicina III e Professor Catedrático da Faculdade de Medicina da Universidade de Coimbra

Keywords:

Unknown primary tumour, positron emission tomography, diagnosis

Abstract

In Internal Medicine we are frequently confronted with the
diagnosis of advanced malignant disease, in patients without previous tumour diagnosis. The localization of the primary tumour
is fundamental for the patient treatment. In some cases, although exhaustive investigation is carried out, the primary site remains obscure, even in the presence of metastasis.
The Positron Emission Tomography (PET), using 18Fluoro-DGlucose (18FDG) is a whole body, multi-organ, non invasive exam,
used to diagnose and stage a large number of malignancies, including the occult tumour.
We present two female patients with advanced malignant disease, in whom the 18FDG-PET was essential for the diagno

Downloads

Download data is not yet available.

References

Mintzer MD, Warhol M, Martin AM, Greene G. Cancer of unknown primary: catching aproches. A multidisciplinary case presentation from the Joan Karnell Cancer Center of Pennsylvania Hospital. The Oncologist 2004; 9:330-338.

van de Wouw AJ, Jansen RLH, Spell EJM, et al. The unknown biology of the unknown primary tumor: a literature review. Ann Onc 2003; 14:191-196.

Hillen HFP. Unknown primary tumors. Postgrad Med J 2000; 76:690-693.

Stone RM. Metastatic cancer of unknown primary site. Harrisson`s Principles of Internal Medicine on CD ROM, 16th ed, 2005:562-566.

Nunes AP, Fonseca T, Lourenço I et al. Abordagem diagnóstica do doente com neoplasia oculta. Medicina Interna 2005; 21(12):82-88.

Brito D, Fiúza T, Santos A. Neoplasia oculta primária: estudo retrospectivo de 3 anos num serviço de Medicina Interna. Acta Médica Portuguesa 1991; 4:117-121.

Kole AC, Nieweg OE, Pruim J et al. Detection of unknown occult primary tumors using positron emission tomography. Cancer 1998; 82(6):1160-1166.

Lassen U, Daugaard G, Eigtved A et al. 18FDG-PET whole body positron emission tomography (PET) in patients with unknown primary tumors (UPT). Eur J Cancer 1999; 35:1076-1082

Bohuslavizki KH, Klutmann S, Kroger S et al. FDG-PET detection of unknown primary tumors. J Nucl Med 2000; 41(5):816-822.

Rades D, Kuhnel G, Wildfang I et al. Localised disease in cancer of unknown primary (CUP): the value of positron emission tomography (PET) for individual therapeutic management. Ann Onc 2001; 12(11):1605-1609.

Wen PY, Black PM, Loeffler JS. Metastatic brain cancer. Principles and practice of oncology on CD ROM, 6th ed, 2001:2655-2667.

Bartlett DL. Peritoneal carcinomatosis. Principles and Practice of Oncology on CD ROM, 6th ed, 2001: 2561-2567.

Marincola FM, Schwartzentruber DJ. Malignant ascites. Principles and practice of oncology on CD ROM, 6th ed, 2001: 2745-2746.

Suzuki A, Kawano T, Takashi N et al. Value of 18F-FDG PET in the detection of peritoneal carcinomatosis. Eur J Med Mol Imaging 2004;

(10):1413-1420.

Turlakow A, Yeung HW, Salmon AS. Peritoneal carcinomatosis: role of (18)F-FDG PET. J Nucl Med 2003; 44(9):1407-1412.

Jeong HJ, Chung JK, Kim YK et al. Usefulness of wlole-body 18F-FDG PET in patients with suspected metastatic brain tumors. J Nucl Med 2002; 43(11):1432-1437.

Klee B, Law I, Højgaard L, Kosteljanetz M. Detection of unknown primary tumors in patients with cerebral metastases using whole-body F-fluorodeoxyglucose positron emission tomography. European Journal of Neurology 2002; 9:657-662.

Albertini JL, Belhocine T, Hustinx R et al. Whole-body positron emission tomography using fluorodeoxyglucose in patients with matastases of unknown primary tumors (CUP syndrome). Nuclear Medicine Communications 2002; 24:1081-1086.

Batsis AJ, Morgenthaler TI. Trousseau syndrome and the unknown cancer: use of positron emission tomographic imaging in a patient with a paraneoplastic syndrome. Mayo Clin Proc 2005; 80(4):537-540.

Delgado-Bolton RC, Fernandez-Perez C, Gonzalez-Mate A et al. Meta-analysis of the performance of 18F-FDG PET in primary tumor detection in unknown primary tumors. J Nucl Med 2003; 44(8):1301-1314

Additional Files

Published

2008-06-30

How to Cite

1.
Simões S, Vaio T, Santos A, Santos R, Lapa P, de Lima P, Antunes A, Porto A. Positron Emission Tomography in the diagnosis of an unknown primary tumour. RPMI [Internet]. 2008 Jun. 30 [cited 2024 Sep. 16];15(2):131-6. Available from: https://revista.spmi.pt/index.php/rpmi/article/view/1462

Issue

Vol. 15 No. 2 (2008): Abril/ Junho

Section

Case Reports

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright (c) 2023 Medicina Interna

Open Access

Most read articles by the same author(s)

1 2 3 > >>